Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database

Keyphrases

• National Cohort Study 100%
• Comorbidity 100%
• Cancer Patients 100%
• Head-and-neck Cancer 100%
• Head-and-neck Squamous Cell Carcinoma (HNSCC) 53%
• Head-and-neck 46%
• Comorbidity Index 46%
• Charlson Comorbidity Index 38%
• Radiotherapy 30%
• Overall Survival 23%
• Cancer Mortality 23%
• Non-associated 15%
• Cancer Risk 7%
• Etiology 7%
• Diabetes 7%
• Randomized Trial 7%
• Population-based Cohort Study 7%
• National Population 7%
• Comorbid Conditions 7%
• Congestive Heart Failure 7%
• Liver Disease 7%
• Cerebrovascular Disease 7%
• Prognostic Impact 7%
• National Cohort 7%
• 5-year Survival 7%
• Chronic Pulmonary Disease 7%
• Survival Probability 7%
• Patient Health 7%
• Prognostic Stage 7%
• National Patient Registry 7%
• Peptic Ulcer Disease 7%
• Chronological Age 7%
• Modified Index 7%

Immunology and Microbiology

• Comorbidity 100%
• Neck 100%
• Squamous Cell 29%
• Overall Survival 16%
• Age 4%
• Survival Rate 4%